pr-104
Small moleculeexperimental
Clinical trial activity
8 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2005 (NCT00349167)
Timeline
Indications
Mechanism of action
- DNACROSS-LINKING AGENT
DNA cross-linking agent
Chemistry & pharmacology
Loading structure…
SMILES
CS(=O)(=O)OCCN(CCBr)c1c(C(=O)NCCOP(=O)(O)O)cc([N+](=O)[O-])cc1[N+](=O)[O-]- Mol. weight
- 579.28 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297321 ↗
Also known as
- pr-104
- pr-104
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01037556 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2010 | Proacta, Incorporated |
| NCT00862082 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2009 | Proacta, Incorporated |
| NCT00862134 | Phase 2 | Mar 1, 2009 | Proacta, Incorporated |
| NCT00616213 | Phase 1 | Feb 1, 2008 | Proacta, Incorporated |
| NCT00544674 | Phase 2 | Aug 1, 2007 | Proacta, Incorporated |
| NCT00459836 | Phase 1 | Feb 1, 2007 | Proacta, Incorporated |
| NCT01358227 | Phase 1 | Dec 1, 2006 | Proacta, Incorporated, University of Auckland |
| NCT00349167 | Phase 1 | Dec 1, 2005 | National Cancer Institute (NCI), Proacta, Incorporated, University of California, Los Angeles |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Proacta, Incorporated | For profit | 8 | 8 | 2 | 2005 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2005 |
| University of Auckland | Academic/Hospital | 1 | 0 | 1 | 2006 |
| University of California, Los Angeles | Academic/Hospital | 1 | 0 | 1 | 2005 |
4 organizations
Page 1 / 1